The anxiolytic etifoxine can continue to be given to patients with anxiety disorders provided they have not previously experienced severe dermatological or hepatic side-effects after taking the drug, the European Medicines Agency has advised.
Following a benefit/risk review triggered by the French regulator ANSM in mid-2021, the EMA’s human drugs committee, the CHMP, assessed...